Met Life Investment Management, LLC Nuvation Bio Inc. Transaction History

Met Life Investment Management, LLC

  • $16.6 Billion
  • Q2 2024

A detailed history of Met Life Investment Management, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 105,678 shares of NUVB stock, worth $247,286. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,678
Previous 85,391 23.76%
Holding current value
$247,286
Previous $310,000 0.65%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$2.58 - $3.69 $52,340 - $74,859
20,287 Added 23.76%
105,678 $308,000
Q1 2024

May 14, 2024
BUY
$1.46 - $3.97 $124,670 - $339,002
85,391 New
85,391 $310,000
Q3 2023

May 09, 2024
BUY
$1.26 - $2.1 $16,374 - $27,291
12,996 Added 19.6%
79,288 $106,000
Q2 2023

Apr 29, 2024
BUY
$1.56 - $1.84 $123,689 - $145,889
79,288 New
79,288 $142,000
Q2 2023

Aug 10, 2023
BUY
$1.56 - $1.84 $20,273 - $23,912
12,996 Added 19.6%
79,288 $142,000
Q1 2023

May 09, 2024
BUY
$1.6 - $2.48 $106,067 - $164,404
66,292 New
66,292 $110 Million
Q1 2023

May 15, 2023
BUY
$1.6 - $2.48 $37,606 - $58,289
23,504 Added 54.93%
66,292 $110,000
Q4 2022

May 10, 2024
SELL
$1.68 - $2.5 $37,045 - $55,127
-22,051 Reduced 34.01%
42,788 $82,000
Q4 2022

Jun 14, 2023
SELL
$1.68 - $2.5 $39,486 - $58,760
-23,504 Reduced 35.46%
42,788 $82,000
Q4 2022

Mar 22, 2023
SELL
$1.68 - $2.5 $37,045 - $55,127
-22,051 Reduced 34.01%
42,788 $82,000
Q4 2022

Feb 15, 2023
SELL
$1.68 - $2.5 $37,045 - $55,127
-22,051 Reduced 34.01%
42,788 $82,000
Q3 2022

Jun 14, 2023
SELL
$0.29 - $4.04 $421 - $5,870
-1,453 Reduced 2.19%
64,839 $145,000
Q2 2022

May 10, 2024
SELL
$3.24 - $5.85 $80,468 - $145,290
-24,836 Reduced 27.7%
64,839 $210,000
Q2 2022

Jun 20, 2023
SELL
$3.24 - $5.85 $4,707 - $8,500
-1,453 Reduced 2.19%
64,839 $210,000
Q2 2022

Mar 22, 2023
SELL
$3.24 - $5.85 $80,468 - $145,290
-24,836 Reduced 27.7%
64,839 $210,000
Q2 2022

Aug 11, 2022
SELL
$3.24 - $5.85 $80,468 - $145,290
-24,836 Reduced 27.7%
64,839 $210,000
Q1 2022

May 10, 2024
BUY
$4.6 - $8.83 $412,504 - $791,830
89,675 New
89,675 $471,000
Q1 2022

Jun 20, 2023
BUY
$4.6 - $8.83 $107,561 - $206,471
23,383 Added 35.27%
89,675 $471,000
Q1 2022

Mar 22, 2023
BUY
$4.6 - $8.83 $147,085 - $282,339
31,975 Added 55.42%
89,675 $471,000
Q1 2022

May 12, 2022
BUY
$4.6 - $8.83 $147,085 - $282,339
31,975 Added 55.42%
89,675 $472,000
Q4 2021

May 17, 2024
BUY
$7.75 - $10.05 $249,154 - $323,097
32,149 Added 125.82%
57,700 $490,000
Q4 2021

Jun 21, 2023
SELL
$7.75 - $10.05 $66,588 - $86,349
-8,592 Reduced 12.96%
57,700 $490,000
Q4 2021

Mar 22, 2023
BUY
$7.75 - $10.05 $249,154 - $323,097
32,149 Added 125.82%
57,700 $490,000
Q4 2021

Feb 15, 2022
BUY
$7.75 - $10.05 $249,154 - $323,097
32,149 Added 125.82%
57,700 $490,000
Q3 2021

May 17, 2024
BUY
$7.78 - $10.0 $66,573 - $85,570
8,557 Added 50.35%
25,551 $253,000
Q3 2021

Jun 21, 2023
SELL
$7.78 - $10.0 $316,964 - $407,410
-40,741 Reduced 61.46%
25,551 $253,000
Q3 2021

Mar 22, 2023
BUY
$7.78 - $10.0 $66,573 - $85,570
8,557 Added 50.35%
25,551 $253,000
Q3 2021

Nov 15, 2021
BUY
$7.78 - $10.0 $66,573 - $85,570
8,557 Added 50.35%
25,551 $254,000
Q2 2021

May 17, 2024
SELL
$9.22 - $14.48 $630,620 - $990,388
-68,397 Reduced 80.1%
16,994 $158,000
Q2 2021

Jun 21, 2023
SELL
$9.22 - $14.48 $454,527 - $713,835
-49,298 Reduced 74.36%
16,994 $158,000
Q2 2021

Mar 22, 2023
SELL
$9.22 - $14.48 $237,820 - $373,497
-25,794 Reduced 60.28%
16,994 $158,000
Q2 2021

Aug 16, 2021
BUY
$9.22 - $14.48 $156,684 - $246,073
16,994 New
16,994 $158,000

Others Institutions Holding NUVB

# of Institutions
152
Shares Held
123M
Call Options Held
9.7K
Put Options Held
6.5K
View Full List

About Nuvation Bio Inc.

NUVB Quotes by TradingView
  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email